Dongrui Ray Lu

TL;DR: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.

TL;DR: The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunit inib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.

TL;DR: Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure and the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.

TL;DR: This research highlights the need to understand more fully the role of “cell reprograming” in the development of Parkinson’s disease and its role in cancer.

TL;DR: The addition of adjuvant palbociclib to standard ET did not improve outcomes over ET alone, suggesting no benefit from the agent in reducing the incidence of early relapse in pts with lower-stage HR+/HER2- breast cancer.